top of page

Europe, Male 36, GBM, Stage IV, He Could Walk Again in 6 months with ECCT cancer treatment

An unbelievable journey shared from a late stage GBM survivor with ECCT:

In the face of glioblastoma, GU (nickname, verifiable), a European, 36-year-old male, began his journey to fight cancer on 3 Apr 2021 when a right temporoparietal mass was discovered.

cancer treatment

He underwent gross total resection on 7 Apr 2021, followed by cancer treatment radiotherapy (60 Gy /30 Fr) and Temozolomide (75 mg/m2/day) from 20 Apr 2021 to 1 June 2021.

brain cancer treatment

After a month, he found himself bedridden unable to walk, move, or use his left arm. His oncology then changes his regime of Temozolomide dosage to 150 mg/m2, 5 days per cycle, with each cycle lasting 28 days. Unfortunately, after six cycles of Temozolomide, the tumor worsened.

gbm cancer treatment
gbm cancer treatment
gbm cancer treatment

On 18 Nov 2021, a glimmer of hope emerged him with the introduction of ECCT and his oncology agreed to try ECCT given no other feasible option possible for him. He without hesitation underwent ECCT treatment for three months. He started with five days per week, with sessions starting from 10 minutes increasingly day by day to total 4 hours a day.

gbm cancer treatment

Encouragingly, after six months of unwavering dedication to ECCT, he could walk and move his left arm. MRI show a significant decrease in tumor size. It was a sight that defied all odds and filled the hearts of many with hope.

gbm cancer treatment

May 2023, 18 months after ECCT treatment, GU's MRI follow-up shows stability in his condition, with no neurological deficits other than left arm numbness. He wish to share his experience and the impact of ECCT on him as a potential alternative option for other glioblastoma fighter out there as it has offered him a hope at time of desperate and an alternative approach to managing the disease.


面对胶质母细胞瘤,36 岁的欧洲男性 GU(昵称)于 2021 年 4 月 3 日开始了他的抗癌之旅,当时发现了右侧颞顶肿块。他于 2021 年 4 月 7 日接受了大切除,随后于 2021 年 4 月 20 日至 2021 年 6 月 1 日接受了放疗(60 Gy/30 Fr)和替莫唑胺(75 mg/m2/天)。一个月后,他发现自己无法行走、移动或使用左臂。然后,他的肿瘤学将替莫唑胺剂量方案更改为150mg / m2,每个周期5天,每个周期持续28天。不幸的是,在替莫唑胺六个周期后,肿瘤恶化。

在2021 年 11 月 18 日,他开始了 ECCT(电容性癌症疗法)的治疗,他看到了一线希望,他的肿瘤医生也同意让他尝试 ECCT,因为他已别无选择了。

GU接受了三个月的ECCT治疗。他从每周五天开始,每天从 10 分钟开始,每天增加到总共 4 小时。令人鼓舞的是,经过六个月对ECCT的坚定不移的奉献,他开始可以走路和移动左臂。MRI显示肿瘤大小显着减小。这一景象,使许多人的心中充满了希望。

2023 年 5 月,即 ECCT 治疗 18 个月后,GU 的 MRI 随访显示他的病情稳定,除了左臂麻木外,没有神经功能障碍。GU希望分享他的经验以及ECCT对他的影响,作为其他胶质母细胞瘤战士的潜在替代选择,因为它为他在绝望的时候提供了希望和另一种管理疾病的方法。

bottom of page